Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Oct. 19 — The Senate's medical innovation bill needs to include mandatory funding for the National Institutes of Health and the Food and Drug Administration, research advocacy group Research!America told Senate leaders in an Oct. 19 letter.
“Our nation need not abide the level of human suffering and the weight of healthcare costs that attend health conditions we can conquer. A funding boost for NIH will empower our nation to fight harder and find answers faster,” the letter said. “The logic for mandatory FDA funding is equally straightforward. If FDA is given additional responsibilities without additional resources, the stage will be set for slowdowns, not faster speeds, in the review of new medical products. Neither patients nor taxpayers can afford this worst case scenario.”
A draft bill expected this fall from the Senate Health, Education, Labor, and Pensions Committee is largely viewed as the companion bill to the House-passed 21st Century Cures bill (H.R. 6). But there have been questions about whether mandatory funding provided in H.R. 6 will be included in the Senate version. HELP's top Democrat, Sen. Patty Murray (D-Wash.), said she won't support a bill without more funding for the NIH; HELP Chairman Lamar Alexander (R-Tenn.), said he'd consider it but has some questions.
A Democratic aide told Bloomberg BNA Oct. 19 that there may be a draft bill out by the end of October, but that the primary goal is to develop “thoughtful, bipartisan” legislation.
The Research!America letter is available at http://src.bna.com/D7.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)